Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Salvage Prostate Brachytherapy for Postradiation Local Failure

  • Chapter
  • First Online:
Management of Prostate Cancer

  • 1263 Accesses

Abstract

For a long time, one drawback of both prostate external-beam radiotherapy (EBRT) and brachytherapy was linked to the risk of morbidity associated with any local salvage therapy such as radical prostatectomy. For this reason, some patients may choose primary radical prostatectomy, following which salvage local EBRT still remains a possible curative salvage option, as recommended by many urologists. Life-long androgen deprivation therapy (ADT) was the standard of care for patients with rising PSA levels after primary radiotherapy [1, 2]. However, ADT is associated with a number of toxicities, such as erectile dysfunction, decreased libido, gynecomastia, hot flashes, osteoporosis, and metabolic syndrome. An alternative that has recently emerged is intermittent life-long androgen deprivation, which in theory results in an improvement in quality of life compared to continuous androgen deprivation therapy, though this may not be the case [3–5]. However, all patients are doomed to progress to castrate-resistant prostate cancer and develop metastases, making this treatment palliative only.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR, Cancer of the Prostate Strategic Urological Research E. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008;112(2):307–14.

    Google Scholar 

  2. Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int. 2010;105(2):191–201.

    Article  CAS  PubMed  Google Scholar 

  3. Crook JM, O’Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367(10):895–903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368(14):1314–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016;2(4):453–61.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, Anderson LL, et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys. 1991;21(3):537–47.

    Article  CAS  PubMed  Google Scholar 

  7. Zagars GK, von Eschenbach AC, Ayala AG, Schultheiss TE, Sherman NE. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer. 1991;68(11):2370–7.

    Article  CAS  PubMed  Google Scholar 

  8. Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002;20(15):3199–205.

    Article  PubMed  Google Scholar 

  9. Zietman AL, Westgeest JC, Shipley WU. Radiation-based approaches to the management of T3 prostate cancer. Semin Urol Oncol. 1997;15(4):230–8.

    CAS  PubMed  Google Scholar 

  10. Crook JM, Perry GA, Robertson S, Esche BA. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology. 1995;45(4):624–31; discussion 31–2.

    Article  CAS  PubMed  Google Scholar 

  11. Dugan TC, Shipley WU, Young RH, Verhey LJ, Althausen AF, Heney NM, et al. Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels. J Urol. 1991;146(5):1313–6.

    CAS  PubMed  Google Scholar 

  12. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41(3):491–500.

    Article  CAS  PubMed  Google Scholar 

  13. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995;32(1):3–12.

    Article  CAS  PubMed  Google Scholar 

  14. Huang KT, Stoyanova R, Walker G, Sandler K, Studenski MT, Dogan N, et al. Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled. Radiother Oncol. 2015;115(1):101–6.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Huang WC, Kuroiwa K, Serio AM, Bianco Jr FJ, Fine SW, Shayegan B, et al. The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncological efficacy of salvage ablative therapies. J Urol. 2007;177(4):1324–9; quiz 591.

    Article  PubMed  Google Scholar 

  16. Leibovici D, Chiong E, Pisters LL, Guo CC, Ward JF, Andino L, et al. Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy. J Urol. 2012;188(1):98–102.

    Article  PubMed  Google Scholar 

  17. Lo AC, Morris WJ, Pickles T, Keyes M, McKenzie M, Tyldesley S. Patterns of recurrence after low-dose-rate prostate brachytherapy: a population-based study of 2223 consecutive low- and intermediate-risk patients. Int J Radiat Oncol Biol Phys. 2015;91(4):745–51.

    Article  PubMed  Google Scholar 

  18. Stone NN, Stock RG, White I, Unger P. Patterns of local failure following prostate brachytherapy. J Urol. 2007;177(5):1759–63; discussion 63–4.

    Article  PubMed  Google Scholar 

  19. Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK. A dose–response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41(1):101–8.

    Article  CAS  PubMed  Google Scholar 

  20. Lepinoy A, Cochet A, Cueff A, Cormier L, Martin E, Maingon P, et al. Pattern of occult nodal relapse diagnosed with (18)F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy. Radiother Oncol. 2014;111(1):120–5.

    Article  PubMed  Google Scholar 

  21. Arrayeh E, Westphalen AC, Kurhanewicz J, Roach 3rd M, Jung AJ, Carroll PR, et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012;82(5):e787–93.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Chopra S, Toi A, Taback N, Evans A, Haider MA, Milosevic M, et al. Pathological predictors for site of local recurrence after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(3):e441–8.

    Article  PubMed  Google Scholar 

  23. Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007;69(1):62–9.

    Article  PubMed  Google Scholar 

  24. Anwar M, Westphalen AC, Jung AJ, Noworolski SM, Simko JP, Kurhanewicz J, et al. Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology. Radiother Oncol. 2014;110(2):303–8.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Menard C, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(2):425–30.

    Article  PubMed  Google Scholar 

  26. Testa C, Schiavina R, Lodi R, Salizzoni E, Corti B, Farsad M, et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology. 2007;244(3):797–806.

    Article  PubMed  Google Scholar 

  27. Van den Bergh L, Koole M, Isebaert S, Joniau S, Deroose CM, Oyen R, et al. Is there an additional value of (1)(1)C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? Int J Radiat Oncol Biol Phys. 2012;83(5):1486–92.

    Article  PubMed  Google Scholar 

  28. Chang JH, Lim Joon D, Davis ID, Lee ST, Hiew CY, Esler S, et al. Comparison of [(11)C]choline positron emission tomography with T2- and diffusion-weighted magnetic resonance imaging for delineating malignant intraprostatic lesions. Int J Radiat Oncol Biol Phys. 2015;92(2):438–45.

    Article  PubMed  Google Scholar 

  29. Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology. 1999;54(5):880–3.

    Article  CAS  PubMed  Google Scholar 

  30. Burri RJ, Stone NN, Unger P, Stock RG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;77(5):1338–44.

    Article  PubMed  Google Scholar 

  31. Nguyen PL, D’Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007;110(7):1417–28.

    Article  PubMed  Google Scholar 

  32. Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol. 2015;67(6):1009–16.

    Article  PubMed  Google Scholar 

  33. Roach 3rd M. Natural history after biochemical failure following dose-escalated external beam radiation: an opportunity to improve outcomes? Eur Urol. 2015;67(6):1017–8.

    Article  PubMed  Google Scholar 

  34. Peters M, van der Voort van Zyp JR, Moerland MA, Hoekstra CJ, van de Pol S, Westendorp H, et al. Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer. Brachytherapy. 2016.

    Google Scholar 

  35. Peters M, van der Voort van Zyp JR, Moerland MA, Hoekstra CJ, van de Pol S, Westendorp H, et al. Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy. Radiother Oncol. 2016.

    Google Scholar 

  36. Kaljouw E, Pieters BR, Kovacs G, Hoskin PJ. A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study. Radiother Oncol. 2016;118(1):122–30.

    Article  PubMed  Google Scholar 

  37. Tretiakova MS, Wei W, Boyer HD, Newcomb LF, Hawley S, Auman H, et al. Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies. Prostate Cancer Prostatic Dis. 2016.

    Google Scholar 

  38. Zellweger T, Gunther S, Zlobec I, Savic S, Sauter G, Moch H, et al. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer. 2009;124(9):2116–23.

    Article  CAS  PubMed  Google Scholar 

  39. Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, et al. DNA-PKcs-mediated transcriptional regulation drives prostate cancer progression and metastasis. Cancer Cell. 2015;28(1):97–113.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Crehange G, Roach 3rd M, Martin E, Cormier L, Peiffert D, Cochet A, et al. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? Cancer Radiother. 2014;18(5–6):524–34.

    Article  CAS  PubMed  Google Scholar 

  41. Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, et al. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int. 2009;104(5):600–4.

    Article  PubMed  Google Scholar 

  42. Allen GW, Howard AR, Jarrard DF, Ritter MA. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer. 2007;110(7):1405–16.

    Article  PubMed  Google Scholar 

  43. Grado GL. Benefits of brachytherapy as salvage treatment for radiorecurrent localized prostate cancer. Urology. 1999;54(2):204–7.

    Article  CAS  PubMed  Google Scholar 

  44. Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, et al. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(2):370–7.

    Article  PubMed  Google Scholar 

  45. Moman MR, van der Poel HG, Battermann JJ, Moerland MA, van Vulpen M. Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy. 2010;9(2):119–25.

    Article  PubMed  Google Scholar 

  46. Sasaki H, Kido M, Miki K, Kuruma H, Takahashi H, Aoki M, et al. Salvage partial brachytherapy for prostate cancer recurrence after primary brachytherapy. Int J Urol. 2014;21(6):572–7.

    Article  PubMed  Google Scholar 

  47. Nguyen PL, Chen MH, D’Amico AV, Tempany CM, Steele GS, Albert M, et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer. 2007;110(7):1485–92.

    Article  PubMed  Google Scholar 

  48. Peters M, Maenhout M, van der Voort van Zyp JR, Moerland MA, Moman MR, Steuten LM, et al. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life. Radiother Oncol. 2014;112(1):77–82.

    Article  PubMed  Google Scholar 

  49. Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology. 1999;53(1):2–10.

    Article  CAS  PubMed  Google Scholar 

  50. Lacy JM, Wilson WA, Bole R, Chen L, Meigooni AS, Rowland RG, et al. Salvage brachytherapy for biochemically recurrent prostate cancer following primary brachytherapy. Prostate Cancer. 2016;2016:9561494.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Chen CP, Weinberg V, Shinohara K, Roach 3rd M, Nash M, Gottschalk A, et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013;86(2):324–9.

    Article  PubMed  Google Scholar 

  52. Jo Y, Fujii T, Hara R, Yokoyama T, Miyaji Y, Yoden E, et al. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy – preliminary results. BJU Int. 2012;109(6):835–9.

    Article  PubMed  Google Scholar 

  53. Yamada Y, Kollmeier MA, Pei X, Kan CC, Cohen GN, Donat SM, et al. A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy. 2014;13(2):111–6.

    Article  PubMed  Google Scholar 

  54. Chung HT, Loblaw A, D’Alimonte L, Ravi A, Haider MA, Morton G. Pilot study of focal salvage high-dose rate (HDR) prostate brachytherapy in patients with local recurrence after definitive external-beam radiotherapy (XRT). J Clin Oncol. 2014: ASCO Vol 32, No 4_suppl, 2014: 264.

    Google Scholar 

  55. Guimas V, Quivrin M, Bertaut A, Martin E, Maingon P, Mazoyer F, Cormier L, Crehange G. Focal or whole-gland salvage prostate brachytherapy with iodine seeds with or without a rectal spacer for postradiotherapy local failure: how best to spare the rectum? Brachytherapy. 2016;15(4):406–11.

    Google Scholar 

  56. Rose JN, Crook JM, Pickles T, Keyes M, Morris WJ. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: association between dose and late toxicity. Brachytherapy. 2015;14(3):342–9.

    Article  PubMed  Google Scholar 

  57. Peters M, Hoekstra CJ, van der Voort van Zyp JR, Westendorp H, van de Pol SM, Moerland MA, et al. Rectal dose constraints for salvage iodine-125 prostate brachytherapy. Brachytherapy. 2016;15(1):85–93.

    Article  PubMed  Google Scholar 

  58. Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012;11(1):6–19.

    Article  PubMed  Google Scholar 

  59. Peters M, van der Voort van Zyp J, Hoekstra C, Westendorp H, van de Pol S, Moerland M, et al. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints. Radiother Oncol. 2015;117(2):262–9.

    Article  PubMed  Google Scholar 

  60. Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach 3rd M, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 2007;67(4):1106–12.

    Article  PubMed  Google Scholar 

  61. Roach 3rd M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26(4):585–91.

    Article  PubMed  Google Scholar 

  62. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–73.

    Article  CAS  PubMed  Google Scholar 

  63. D’Amico AV, Chen MH, Renshaw A, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2015;314(12):1291–3.

    Article  PubMed  Google Scholar 

  64. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365(2):107–18.

    Article  CAS  PubMed  Google Scholar 

  65. Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach 3rd M, et al. Patterns of local failure following radiation therapy for prostate cancer. J Urol. 2015;194(4):977–82.

    Article  PubMed  Google Scholar 

  66. Krauss DJ, Hu C, Bahary JP, Souhami L, Gore EM, Chafe SM, et al. Importance of local control in early-stage prostate cancer: outcomes of patients with positive post-radiation therapy biopsy results treated in RTOG 9408. Int J Radiat Oncol Biol Phys. 2015;92(4):863–73.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Smith D, Plowman PN. Recovery of hormone sensitivity after salvage brachytherapy for hormone refractory localized prostate cancer. Int Braz J Urol. 2010;36(3):283–91.

    Article  PubMed  Google Scholar 

  68. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV, et al. Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10(9):1081–7.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Centre Georges François Leclerc, 1 Rue du Professeur Marion, F-21000, Dijon, France

    Gilles Créhange

  2. Department of Radiation Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, 94143, San Francisco, CA, USA

    I-Chow Hsu, Albert J Chang & Mack Roach III

Authors
  1. Gilles Créhange
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I-Chow Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Albert J Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mack Roach III
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gilles Créhange .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Hôpital Albert Michallon, Grenoble, France

    Michel Bolla

  2. Department of Urology, University Hospitals Leuven, Leuven, Belgium

    Hendrik van Poppel

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Créhange, G., Hsu, IC., Chang, A.J., Roach, M. (2017). Salvage Prostate Brachytherapy for Postradiation Local Failure. In: Bolla, M., van Poppel, H. (eds) Management of Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-42769-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42769-0_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42768-3

  • Online ISBN: 978-3-319-42769-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation